- Deltex Medical Group, the global leader in oesophageal Doppler monitoring (ODM), posts an operating loss of GBP3.5m for the year to the end of December, up from GBP3.0m in 2014.

Revenues were flat at GBP6.4m an gross margins falling to 63% from 70%, reflecting investment in long term improvements.

Chairman Nigel Keen said: "Deltex made significant progress in 2015 despite continuing difficulties in the UK. Total export sales were approximately 20% ahead with over 40% growth in the USA, which has become our key territory for development. Whilst trading in the UK will continue to be challenging, we expect this overseas success to drive overall group growth going forward.

"We are focused on increasing the number of US platform accounts, with the consequent probe revenue run-rate, and on improving margins, reducing overheads and adding incremental revenue streams in the business as a whole. Successful implementation of these key tasks will deliver the operating cash required for us to continue to grow our business from our own internally generated resources."

At 8:13am: [LON:DEMG] Deltex Medical Group PLC share price was -0.38p at 4.25p

Story provided by